title: Adenovirus-based vaccine prevents pneumonia in ferrets challenged with the SARS coronavirus and stimulates robust immune responses in macaques.
abstract: A ferret model of severe acute respiratory syndrome (SARS)-CoV infection was used to evaluate the efficacy of an adenovirus vaccine. Animals were subjected to heterologous prime-boost using vectors from human serotype 5 and chimpanzee derived adenoviruses (human AdHu5 and chimpanzee AdC7) expressing spike protein followed by intranasal challenge with SARS-CoV. Vaccination led to a substantial reduction in viral load and prevented the severe pneumonia seen in unvaccinated animals. The same prime-boost strategy was effective in rhesus macaques in eliciting SARS-CoV specific immune responses. These data indicate that a heterologous adenovirus-based prime-boost vaccine strategy could safely stimulate strong immunity that may be needed for complete protection against SARS-CoV infection.
authors.affiliation: Special Pathogens Program, National Microbiology Laboratory, Health Canada, Canadian Science Centre for Human and Animal Health, Department of Medical Microbiology, University of Manitoba, Winnipeg, Canada.
authors.forename: Gary P
authors.initials: GP
authors.lastname: Kobinger
authors.forename: Joanita M
authors.initials: JM
authors.lastname: Figueredo
authors.forename: Thomas
authors.initials: T
authors.lastname: Rowe
authors.forename: Yan
authors.initials: Y
authors.lastname: Zhi
authors.forename: Guangping
authors.initials: G
authors.lastname: Gao
authors.forename: Julio C
authors.initials: JC
authors.lastname: Sanmiguel
authors.forename: Peter
authors.initials: P
authors.lastname: Bell
authors.forename: Nelson A
authors.initials: NA
authors.lastname: Wivel
authors.forename: Lois A
authors.initials: LA
authors.lastname: Zitzow
authors.forename: Douglas B
authors.initials: DB
authors.lastname: Flieder
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Hogan
authors.forename: James M
authors.initials: JM
authors.lastname: Wilson
mesh_terms: D000256:Adenoviridae / Q000276:immunology*; D000281:Administration, Intranasal; D000818:Animals; D000956:Antigens, Viral / Q000276:immunology; D001402:B-Lymphocytes / Q000276:immunology; D004195:Disease Models, Animal; D005289:Ferrets; D006801:Humans; D007117:Immunization, Secondary / Q000379:methods; D008168:Lung / Q000276:immunology / Q000473:pathology / Q000821:virology; D008253:Macaca mulatta; D011014:Pneumonia / Q000276:immunology* / Q000517:prevention & control; D045473:Severe acute respiratory syndrome-related coronavirus / Q000254:growth & development / Q000276:immunology*; D045169:Severe Acute Respiratory Syndrome / Q000276:immunology* / Q000517:prevention & control; D013601:T-Lymphocytes / Q000276:immunology; D014611:Vaccination / Q000379:methods; D014765:Viral Vaccines / Q000008:administration & dosage / Q000276:immunology*
chemical_list: D000956:Antigens, Viral; D014765:Viral Vaccines